Effect of silibinin-loaded nano-niosomal coated with trimethyl chitosan on miRNAs expression in 2D and 3D models of T47D breast cancer cell line

References

• American Cancer Society. Available from: https://www.cancer.org/ (last accessed August 18, 2016).
   Google Scholar
• Agati G, Azzarello E, Pollastri S, Tattini M. Flavonoids as antioxidants in plants: location and functional significance. Plant Sci. 2012;196:67–76.
   PubMed Web of Science ®Google Scholar
• Noh E-M, Yi MS, Youn HJ, et al. Silibinin enhances ultraviolet B-induced apoptosis in mcf-7 human breast cancer cells. J Breast Cancer. 2011;14:8–13.
   PubMed Web of Science ®Google Scholar
• Lee S-O, Jeong Y-J, Im HG, et al. Silibinin suppresses PMA-induced MMP-9 expression by blocking the AP-1 activation via MAPK signaling pathways in MCF-7 human breast carcinoma cells. Biochem Biophys Res Commun. 2007;354:165–171.
   PubMed Web of Science ®Google Scholar
• Duan W-J, Li Q-S, Xia M-Y, et al. Silibinin activated p53 and induced autophagic death in human fibrosarcoma HT1080 cells via reactive oxygen species-p38 and c-Jun N-terminal kinase pathways. Biol Pharm Bull. 2011;34:47–53.
   PubMed Web of Science ®Google Scholar
• Kim TH, Woo JS, Kim YK, Kim KH. Silibinin induces cell death through reactive oxygen species-dependent downregulation of notch-1/ERK/Akt signaling in human breast cancer cells. J Pharmacol Exp Ther. 2014;349:268–278.
   PubMed Web of Science ®Google Scholar
• Tiwari P, Kumar A, Balakrishnan S, et al. Silibinin-induced apoptosis in MCF7 and T47D human breast carcinoma cells involves caspase-8 activation and mitochondrial pathway. Cancer Investig. 2011;29:12–20.
   PubMed Web of Science ®Google Scholar
• Flaig TW, Gustafson DL, et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs. 2007;25:139–146.
   PubMed Web of Science ®Google Scholar
• Flaig T, Agarwal R, Su L-J, et al. A phase I study of silibinin in hormone refractory prostate cancer. JCO. 2005;23:4698.
   Google Scholar
• Singh RP, Raina K, Deep G, et al. Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling. Clin Cancer Res. 2009;15:613–621.
   PubMed Web of Science ®Google Scholar
• Agarwal C, Wadhwa R, Deep G, et al. Anti-cancer efficacy of silybin derivatives – a structure-activity relationship. PLoS One. 2013;8:e60074.
   PubMed Web of Science ®Google Scholar
• Deep G, Agarwal R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev. 2010;29:447–463.
   PubMed Web of Science ®Google Scholar
• Loguercio C, Festi D. Silybin and the liver: from basic research to clinical practice. World J Gastroenterol. 2011;17:2288–2301.
   PubMed Web of Science ®Google Scholar
• El-Ridy MS, Badawi AA, Safar MM, Mohsen AM. Niosomes as a novel pharmaceutical formulation encapsulating the hepatoprotective drug silymarin. Int J Pharm Pharm Sci 2012;4:549–559.
   Web of Science ®Google Scholar
• Moghassemi S, Hadjizadeh A, Hakamivala A, Omidfar K. Growth factor-loaded nano-niosomal gel formulation and characterization. AAPS PharmSciTech. 2017;18:34–41.
   PubMed Web of Science ®Google Scholar
• Moghassemi S, Hadjizadeh A, Omidfar K. Formulation and characterization of bovine serum albumin-loaded niosome. AAPS PharmSciTech. 2017;18:27–33.
   PubMed Web of Science ®Google Scholar
• Moghassemi S, Parnian E, Hakamivala A, et al. Uptake and transport of insulin across intestinal membrane model using trimethyl chitosan coated insulin niosomes. Mater Sci Eng C Mater Biol Appl. 2015;46:333–340.
   PubMed Web of Science ®Google Scholar
• Shirazi H, Daneshpour M, Kashanian S, Omidfar K. Synthesis, characterization and in vitro biocompatibility study of Au/TMC/Fe3O4 nanocomposites as a promising, nontoxic system for biomedical applications. Beilstein J Nanotechnol. 2015;6:1677–89.
   PubMed Web of Science ®Google Scholar
• Xu W, Ling P, Zhang T. Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs. J Drug Deliv. 2013;2013:340315. doi: 10.1155/2013/340315
   PubMedGoogle Scholar
• Yan L-X, Huang X-F, Shao Q, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008;14:2348–2360.
   PubMed Web of Science ®Google Scholar
• Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol. 2014;9:287–314.
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Slack FJ. Oncomirs – microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–269.
   PubMed Web of Science ®Google Scholar
• O'Day E, Ashish L. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res. 2010;12:201.
   PubMed Web of Science ®Google Scholar
• Luo Q, Li X, Li J, et al. MiR-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer. Int J Oncol. 2013;43:1212–1218.
   PubMed Web of Science ®Google Scholar
• Takahashi R-U, Miyazaki H, Ochiya T. The roles of microRNAs in breast cancer. Cancers (Basel). 2015;7:598–616.
   PubMed Web of Science ®Google Scholar
• Howes AL, Richardson RD, Finlay D, Vuori K. 3-Dimensional culture systems for anti-cancer compound profiling and high-throughput screening reveal increases in EGFR inhibitor-mediated cytotoxicity compared to monolayer culture systems. PLoS One. 2014;9:e108283.
   PubMed Web of Science ®Google Scholar
• Edmondson R, Broglie JJ, Adcock AF, Yang L. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol. 2014;12:207–218.
   PubMed Web of Science ®Google Scholar
• Moghassemi S, Hadjizadeh A. Nano-niosomes as nanoscale drug delivery systems: an illustrated review. J Control Release. 2014;185:22–36.
   PubMed Web of Science ®Google Scholar
• Wen Z, Liao Q, Hu Y, et al. A spheroid-based 3-D culture model for pancreatic cancer drug testing, using the acid phosphatase assay. Braz J Med Biol Res. 2013;46:634–642.
   PubMed Web of Science ®Google Scholar
• Gurrapu A, Jukanti R, Bobbala SR, et al. Improved oral delivery of valsartan from maltodextrin based proniosome powders. Adv Powder Technol. 2012;23:583–590.
   Web of Science ®Google Scholar
• Pardakhty A, Varshosaz J, Rouholamini A. In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. Int J Pharm. 2007;328:130–141.
   PubMed Web of Science ®Google Scholar
• Puras G, Mashal M, Zárate J, et al. A novel cationic niosome formulation for gene delivery to the retina. J Control Release. 2014;174:27–36.
   PubMed Web of Science ®Google Scholar
• Abbott A. Cell culture: biology’s new dimension. Nature. 2003;424:870–872.
   PubMed Web of Science ®Google Scholar
• Lee J, Cuddihy MJ, Kotov NA. Three-dimensional cell culture matrices: state of the art. Tissue Eng Part B Rev. 2008;14:61–86.
   PubMed Web of Science ®Google Scholar
• Antoni D, Burckel H, Josset E, Noel G. Three-dimensional cell culture: a breakthrough in vivo. Int J Mol Sci. 2015;16:5517–5527.
   PubMed Web of Science ®Google Scholar
• Shah MY, Pan X, Fix LN, et al. 5-Fluorouracil drug alters the microRNA expression profiles in MCF-7 breast cancer cells J Cell Physiol. 2011;226:1868–1878.
   PubMed Web of Science ®Google Scholar
• Zhang X, Li W. 5-Fluorouracil in combination with cisplatin alters the microRNA expression profile in the CNE nasopharyngeal carcinoma cell line. Mol Med Rep. 2012;6:303–308.
   PubMed Web of Science ®Google Scholar
• Li W, Yuan Y, Huang L, et al. Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells. Diabetes Res Clin Pract. 2012;96:187–195.
   PubMed Web of Science ®Google Scholar
• Fix L, Shah M, Efferth T, et al. MicroRNA expression profile of MCF-7 human breast cancer cells and the effect of green tea polyphenon-60. Cancer Genomics Proteomics. 2010;7:261–277.
   PubMedGoogle Scholar
• Klein U, Lia M, Crespo M, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 2010;17:28–40.
   PubMed Web of Science ®Google Scholar
• Iorio MV, Ferracin M, Liu C-G, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65:7065–7070.
   PubMed Web of Science ®Google Scholar
• Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 2006;66:7390–7394.
   PubMed Web of Science ®Google Scholar
• Nielsen BS, Balslev E, Poulsen TS, et al. miR-21 expression in cancer cells may not predict resistance to adjuvant trastuzumab in primary breast cancer. Front Oncol. 2014;4:Article 207. doi: 10.3389/fonc.2014.00207
   PubMedGoogle Scholar
• Ding X-M. MicroRNAs: regulators of cancer metastasis and epithelial-mesenchymal transition (EMT). Chin J Cancer. 2014;33:140–147.
   PubMed Web of Science ®Google Scholar
• Chang B-p, Wang D-s, Xing J-w, et al. miR-200c inhibits metastasis of breast cancer cells by targeting HMGB1. J Huazhong Univ Sci Technol [Med Sci]. 2014;34:201–206.
   PubMed Web of Science ®Google Scholar
• Tang J, Ahmad A, Sarkar FH. The role of microRNAs in breast cancer migration, invasion and metastasis. Int J Mol Sci. 2012;13:13414–13437.
   PubMed Web of Science ®Google Scholar
• Zuo QF, Zhang R, Li BS, et al. MicroRNA-141 inhibits tumor growth and metastasis in gastric cancer by directly targeting transcriptional co-activator with PDZ-binding motif, TAZ. Cell Death Dis. 2015;6:e1623.
   PubMed Web of Science ®Google Scholar
• Breslin S, O’Driscoll L. The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance. Oncotarget. 2016;7:45745–45756.
   PubMed Web of Science ®Google Scholar
• Sankhyan A, Pawar P. Recent trends in niosome as vesicular drug delivery system. J Appl Pharmaceut Sci. 2012;6:20–32.
   Google Scholar